MétaCan
Menu
Back to cohort
Record W4403537160 · doi:10.1093/jnci/djae262

Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis

2024· review· en· W4403537160 on OpenAlexafffund
Per Karlsson, Anthony Fyles, S. Laura Chang, Bradley A. Arrick, Frederick L. Baehner, Per‐Uno Malmström, Mårten Fernö, Erik Holmberg, Martin Sjöström, Fei‐Fei Liu, David Cameron, Linda Williams, John M.S. Bartlett, Joanna Dunlop, Jacqueline Caldwell, Joseph Loane, Elizabeth Mallon, Tammy Piper, Ian Kunkler, Felix Y. Feng, Corey Speers, Lori J. Pierce, John P. Bennett, Karen J. Taylor

Bibliographic record

VenueJNCI Journal of the National Cancer Institute · 2024
Typereview
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicBreast Cancer Treatment Studies
Canadian institutionsPrincess Margaret Cancer CentreUniversity of Toronto
FundersCanadian Institutes of Health ResearchVetenskapsrådetCancerfondenExact Sciences Corporation
KeywordsMedicineInternal medicineRadiation therapyOncologyBreast cancerHazard ratioAdjuvant radiotherapyMeta-analysisProportional hazards modelCumulative incidenceIncidence (geometry)CancerConfidence intervalCohort

Abstract

fetched live from OpenAlex

BACKGROUND: There are currently no molecular tests to identify individual breast cancers where radiotherapy (RT) offers no benefit. Profile for the Omission of Local Adjuvant Radiotherapy (POLAR) is a 16-gene molecular signature developed to identify low-risk cancers where RT will not further reduce recurrence rates. METHODS: An individual participant data meta-analysis was performed in 623 patients of node-negative estrogen receptor-positive and HER2-negative early breast cancer enrolled in 3 RT randomized trials for whom primary tumor material was available for analysis. A Cox proportional hazards model on time to locoregional recurrence was used to test the interaction between POLAR score and RT. RESULTS: A total of 429 (69%) patients' tumors had a high POLAR score, and 194 (31%) had a low score. Patients with high POLAR score had, in the absence of RT, a 10-year cumulative incidence of locoregional recurrence (20%, 95% confidence interval [CI] = 15% to 26%, vs 5%, [CI] 2% to 11%) for those with a low score. Patients with a high POLAR score had a large benefit from RT (hazard ratio [HR] for RT vs no RT = 0.37, 95% CI = 0.23 to 0.60; P < .001). In contrast, there was no evidence of benefit from RT for patients with a low POLAR score (HR = 0.92, 95% CI = 0.42 to 2.02; P = .832). The test for interaction between RT and POLAR was statistically significant (P = .022). CONCLUSIONS: POLAR is not only prognostic for locoregional recurrence but also predictive of benefit from RT in selected patients. Patients aged 50 years and older with estrogen receptor-positive and HER2-negative disease and a low POLAR score could consider omitting adjuvant RT. Further validation in contemporary clinical cohorts is required.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.083
metaresearch head score (Gemma)0.114
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: Meta-analysis
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.083
Threshold uncertainty score0.440

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0830.114
Meta-epidemiology (narrow)0.0030.001
Meta-epidemiology (broad)0.0110.052
Bibliometrics0.0030.003
Science and technology studies0.0010.001
Scholarly communication0.0040.002
Open science0.0030.002
Research integrity0.0030.003
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.450
GPT teacher head0.498
Teacher spread0.048 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2024
Admission routes2
Has abstractyes

Explore more

Same venueJNCI Journal of the National Cancer InstituteSame topicBreast Cancer Treatment StudiesFrench-language works237,207